U.S. Markets closed

ArQule, Inc. (ARQL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.18-0.05 (-4.07%)
At close: 4:00PM EDT
People also watch
  • What's going on today. Up 26%!
  • See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio.

    • BioLargo’s 10Q states their Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days
    • Woundcare market is over $6 Billion with high growth rate
    • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing
    • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost
    • Sales could commence in first half of 2018
    • Sales and or licensing agreement/s could be very significant
    • Company is now commercializing several other disruptive products in large markets



    Clyra Medical | Make Life Better
  • New DEF 14A filing today shows that a hedge fund, 1 Globe Capital has acquired 3.95 Mill shares since the 4Q filing. For a stock that trades this low, quite a bit of institutional holdings.
  • Weak🌱things🌱united🌱become🌱strong. http://dataunion.tistory.com/1194

    [2016-MAY] ArQule NASDAQ : ARQL Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.6 In other words, the correlation coefficient of the other stoc
  • Can someone tell me (besides the cash) what is keeping ARQL over $1? They have nothing going on anymore, their drugs keep failing.
  • Could very well end in the green now that the entire Tivantinib program is behind them.
  • Very difficult to see ARQL not making a big run north now that it's pulled back this much. performance % (y) is now -14.69%. the other week awesomestoc-ks alerted this company i think. google them .
  • Daiichi did not cancel its partnership with ARQL. Why?
    The western HCC PhIII trial with OS as the primary-endpoint failed. However, the Asian HCCIII trial has PFE as the primary-endpoint and is going on. ARQL knows the failed trial PFS results but did not release them. Consequently, people close to Daiichi and ARQL's sr. management have a very good idea about the chances for the Asian trial to succeed or to fail.

    Both Daiichi and ARQL management are incompetent. Their successful HCC PhII has used one formulation for Tivantinib and the different one for PhIII. The similar blander they have done with failed NSCLC phIII trial. Incredible!
  • So far, Tiva trials were a disaster.
  • The trading setup for ARQL looks very alluring with relative strength index hitting 34.89. The last time things got this interesting there were explosions. if you guys have questions you should ask awes-omeSTOCKS. They often respond to my emails which is helpful.
  • I;m out, bad call. Bad results. If it wasn't for the .50c in cash they have, I would think the stock would be trading around there. Sad sad day for ARQL
  • The next month and a half will be interesting: 4 Tivantinib trials will report the results. One in HCC by Daichi and three in CRC, PC, and HNC by independent researchers.
    These last three nobody pays any attention but there are potential surprises to see.
  • Looks like they like the presentation details.....price action going North!
  • I emailed company, no news, but large holder sold 500K shares, they are not sure yet, but no bad news.
    Probably someone just re-arranged their portfolio.
  • It is about the time ARQL has to file its 4Q 2016 following with a CC.
    Since ARQL's management is quiet, it means they are expecting important news at any time or are reviewing the already available news.
  • I hope you guys are in on this one.
  • This one is ready to pop. Load up. 👍
  • Anybody know when the HCC trial results will be finalized and published?
  • Nice loan approved! Somebody likes ARQL!
  • NEWS released tonight (Saturday) ARQ092 may be a Home Run! Read the PR
    WTG Arqule!